ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag child care academia drug development industry ip

How Orphan Drugs Became a Highly Profitable Industry
Diana Kwon | May 1, 2018 | 10+ min read
Government incentives, advances in technology, and an army of patient advocates have spun a successful market—but abuses of the system and exorbitant prices could cause a backlash.
Concerns over Efficacy and Cost of Muscle Wasting Treatments
Ruth Williams | Nov 11, 2020 | 5 min read
Two new medications for treating a rare and deadly neuromuscular disease have high prices and questionable efficacies, say scientists.
Lilly offers "free" assays
Alla Katsnelson | Jun 15, 2009 | 3 min read
In a new initiative that aims to forge broader partnerships between pharma and academia, Eli Lilly has announced that it will conduct free drug development assays in four therapeutic areas on any compounds academic researchers and small biotechs care to send along. In exchange, the company will get first dibs on any licensing deals or collaborations that promising compounds might yield. What differentiates this initiative from the plethora of partnering opportunities out there, Alan Palkowitz,
Do Patents Promote or Stall Innovation?
Catherine Offord | Jun 1, 2016 | 10 min read
A petition recently filed with the Supreme Court triggers renewed debate about the role of patents in the diagnostics sector.
The Best Places to Work in Industry
Maria Anderson | Jun 20, 2004 | 7 min read
The formula for the best workplace: a product to be proud of, appreciative management, and trustworthy colleagues. That's the opinion of participants in The Scientist's Best Places to Work in Industry survey.Our 2004 survey aimed to define what attracts highly talented workers to a company, and what initiatives keep those workers happy once they sign on. We also asked survey participants to identify the employers who come closest to realizing these ideals.Pride in the product ranked first among
Industry Becomes More Hospitable To The Scientist As New Mother
Ricki Lewis | Jan 8, 1995 | 6 min read
The challenge of successfully combining the demands of family and career may be easing for women scientists in industry. With increasing numbers of women opting to work in private- sector research laboratories--and in the wake of the Family and Medical Leave Act of 1993--many firms have revamped maternity-leave policies to better accommodate new parenthood and the transition back to work. The recently enacted federal law ensures workers in companies with 50 or more employees 12 weeks of unpaid,
Women Make Their Mark As Top Executives In Biotech Industry
Ricki Lewis | Nov 23, 1997 | 8 min read
Being a company president-a job that entails handling day-to- day operations-or a chief executive officer (CEO)-who manages all aspects of a business-involves a unique combination of managerial skills. These roles are especially challenging for women, who are rare at corporate helms, particularly in the two-decade-old biotechnology industry. As biotech matures, the percentage of women at the top is growing. "Biotech is a relatively young industry. People are still working their way up. But we a
Special Report
lone birch tree growing sideways in a field
Amid the Terror of War, Efforts to Keep Science Alive in Ukraine
Katarina Zimmer | Mar 28, 2022 | 10+ min read
Ukrainian scientists and universities face extraordinary challenges as the Russian invasion continues.
Change Broker
Yvonne Greenstreet | May 1, 2009 | 10 min read
Change Broker GlaxoSmithKline is overhauling the drug discovery and development process, one more time. The crucial difference: putting big decisions in the hands of our scientists. By Yvonne Greenstreet T. Walenta lenty has been said about the problems of the pharmaceutical industry and the need to reinvigorate the model. But how do you go about it? What changes can be made that will have notable improvement without risking the cor
What Are The Goals And Priorities Of The Average Scientist?
Lisa Simon | May 26, 1991 | 6 min read
A 17-year-old high school student on the threshold of pursuing a scientific career worries about the public's perception of science and of what research brings to the world. A 72-year-old academic chemist is concerned that young scientists are looking to industry, rather than academia, for fulfilling work. These two people, at opposite ends of a professional lifetime, are different in many ways. But they, and three other researchers of different ages interviewed for this article, agree on many

Run a Search

ADVERTISEMENT